 HOOKIPA Pharma Inc. NASDAQ: HOOK, HOOKIPA, a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced positive interim results on its prophylactic Cytomegalovirus CMV vaccine candidate HB101. HB101 is being investigated in a double-blind Phase 2 clinical trial NCT03629080 to assess safety, immunogenicity and efficacy in patients receiving a kidney transplant from a live donor. 